Elizabeth H. Z. Thompson, Ph.D.

Stories

Acadia pushes Alzheimer's psychosis drug to phase 3 despite missed trial goal

As of September 2026: Designing phase 3 protocol amendments

Acadia Pharmaceuticals said its experimental Alzheimer's psychosis treatment missed the primary goal of a phase 2 trial. The company is advancing remlifanserin to phase 3 anyway, betting a refined study design can turn a near-miss into a win.

Updated Sep 24

Notable Quotes

Our goal with this phase two was to get the information that would help us design our phase three program. And I think from that perspective, it has done what we needed it to do.

from Acadia pushes Alzheimer's psychosis drug to phase 3 despite missed trial goal · Updated Sep 24

We really are trying to get that balance between something that doesn't have a meaningful impact on enrollment but does have an opportunity to increase our overall potential phase 3 efficacy.

from Acadia pushes Alzheimer's psychosis drug to phase 3 despite missed trial goal · Updated Sep 24